PF-07328948 / Pfizer - LARVOL DELTA

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function (clinicaltrials.gov) - P1 | N=26 | Not yet recruiting | Sponsor: Pfizer

New P1 trial • Hepatology

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) (clinicaltrials.gov) - P2 | N=620 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure

C4921008: A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults (clinicaltrials.gov) - P1 | N=26 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Trial completion

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) (clinicaltrials.gov) - P2 | N=620 | Not yet recruiting | Sponsor: Pfizer

New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

C4921008: A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults (clinicaltrials.gov) - P1 | N=26 | Active, not recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Pfizer

New P1 trial

Clinically Advancing BDK Inhibitors. (PubMed, J Med Chem) - "BDK, a negative regulator of the BCKDH complex, is significant in BCAA catabolic dysfunction. A Clinically potential BDK inhibitor, PF-07328948, with excellent drug-like properties, is under phase-1 clinical trials for CVD metabolic disorders."

Journal • Metabolic Disorders

Discovery of First Branched-Chain Ketoacid Dehydrogenase Kinase (BDK) Inhibitor Clinical Candidate PF-07328948. (PubMed, J Med Chem) - "This molecule improves metabolic and heart failure end points in rodent models. PF-07328948 is the first known selective BDK inhibitor candidate to be examined in clinical studies, with Phase 1 single ascending dose data showing good tolerability and a pharmacokinetic profile commensurate with once-daily dosing."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders

PF-07328948, the first BDK inhibitor clinical candidate as a treatment for heart failure (ACS-Fall 2024) - "A cryptic pocket was found which allowed for potency optimization. PF-07328948 was proven to act as a degrader with rodent in vivo studies and preclinical evidence for heart failure efficacy was generated."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders

A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults (clinicaltrials.gov) - P1 | N=86 | Completed | Sponsor: Pfizer | Recruiting ➔ Completed | N=132 ➔ 86

Enrollment change • Trial completion

A Study of Multiple Ascending Doses of PF-07328948 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=108 | Recruiting | Sponsor: Pfizer | Active, not recruiting ➔ Recruiting

Enrollment open

A Study of Multiple Ascending Doses of PF-07328948 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=88 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2024 ➔ Jul 2024 | Trial primary completion date: Jan 2024 ➔ Jul 2024

Enrollment closed • Trial completion date • Trial primary completion date

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Trial completion

A Study of Multiple Ascending Doses of PF-07328948 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open

A Phase 1 Study of Multiple Ascending Doses of PF-07328948 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=1 | Not yet recruiting | Sponsor: Pfizer

New P1 trial